MX2019014772A - Formulaciones en gel de bisfosfocinas y usos de estas. - Google Patents

Formulaciones en gel de bisfosfocinas y usos de estas.

Info

Publication number
MX2019014772A
MX2019014772A MX2019014772A MX2019014772A MX2019014772A MX 2019014772 A MX2019014772 A MX 2019014772A MX 2019014772 A MX2019014772 A MX 2019014772A MX 2019014772 A MX2019014772 A MX 2019014772A MX 2019014772 A MX2019014772 A MX 2019014772A
Authority
MX
Mexico
Prior art keywords
bisphosphocin
gel formulations
gel
formulations
disclosed
Prior art date
Application number
MX2019014772A
Other languages
English (en)
Inventor
Arthur Johnson Keith
A Kates Steven
Original Assignee
Lakewood Amedex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lakewood Amedex Inc filed Critical Lakewood Amedex Inc
Publication of MX2019014772A publication Critical patent/MX2019014772A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Se describen formulaciones en gel que tienen actividad antimicrobiana. Se describen, además, métodos para usar la formulación en gel.
MX2019014772A 2017-06-12 2018-06-12 Formulaciones en gel de bisfosfocinas y usos de estas. MX2019014772A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518262P 2017-06-12 2017-06-12
PCT/US2018/037151 WO2018231863A1 (en) 2017-06-12 2018-06-12 Bisphosphocin gel formulations and uses thereof

Publications (1)

Publication Number Publication Date
MX2019014772A true MX2019014772A (es) 2020-02-07

Family

ID=64562861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014772A MX2019014772A (es) 2017-06-12 2018-06-12 Formulaciones en gel de bisfosfocinas y usos de estas.

Country Status (14)

Country Link
US (4) US11096954B2 (es)
EP (2) EP4241769A3 (es)
JP (2) JP7148994B2 (es)
KR (2) KR20230031370A (es)
CN (1) CN110753549A (es)
AU (3) AU2018282905B2 (es)
BR (2) BR122021011439B1 (es)
CA (1) CA3066722A1 (es)
DK (1) DK3638251T3 (es)
ES (1) ES2981923T3 (es)
FI (1) FI3638251T3 (es)
MX (1) MX2019014772A (es)
PT (1) PT3638251T (es)
WO (1) WO2018231863A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
RU2429850C2 (ru) 2005-04-15 2011-09-27 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
BR122021004504B1 (pt) * 2017-03-10 2022-08-23 Lakewood Amedex, Inc. Uso de um composto antimicrobiano
US12030908B2 (en) 2017-03-10 2024-07-09 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US11377468B2 (en) 2017-03-10 2022-07-05 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
AU2019361999A1 (en) * 2018-10-17 2021-02-25 Lakewood Amedex, Inc. Methods and compositions for treating oral mucositis
EP4373494A1 (en) * 2021-07-22 2024-05-29 Lakewood Amedex, Inc. Methods for preparing bisphosphocins

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
SE8004580L (sv) 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
KR830005852A (ko) * 1980-07-18 1983-09-14 미첼 페터 잭슨 피부와 점막의 비루스 감염치료에 적합한 국소치료제의 제조방법
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
DE3542516A1 (de) 1985-12-02 1987-06-04 Henkel Kgaa Desinfektionsmittel
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
US5153230A (en) 1989-10-06 1992-10-06 Perfective Cosmetics, Inc. Topical skin cream composition
US5167950A (en) 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
US5208015A (en) * 1991-07-23 1993-05-04 Bristol-Myers Squibb Company Topical anti-fungal agents having anti-inflammatory activity
DE4333385C2 (de) 1993-09-30 1997-01-30 Friedrich A Spruegel Flächendesinfektions- und Reinigungsmittel
CZ267396A3 (en) * 1994-03-11 1997-03-12 Procter & Gamble HYDROLYTIC STABLE COSMETIC, PREPARATION WITH LOW pH VALUE CONTAINING ACID ACTIVE SUBSTANCES
FR2718022B1 (fr) 1994-04-01 1996-04-26 Roussel Uclaf Compositions cosmétiques ou dermatologiques et leur préparation.
FR2722102B1 (fr) * 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
US5843998A (en) 1997-06-30 1998-12-01 Song; Jin Skin blemish treatment
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US7868162B2 (en) * 1998-12-30 2011-01-11 Lakewood-Amedex, Inc. Antimicrobial and antiviral compounds and methods for their use
US6627215B1 (en) 1998-12-30 2003-09-30 Oligos Etc. Inc. Devices for improved wound management
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
EP1435970A4 (en) * 2001-10-18 2005-05-04 Ilex Products Inc METHOD OF TREATING SKIN WITH DIPHOSPHONATE DERIVATIVES
MXPA05011208A (es) * 2003-04-24 2005-12-14 Galderma Sa Uso de ivermectina para el tratamiento de desordenes dermatologicos.
CN1687100A (zh) * 2005-04-05 2005-10-26 奥林格斯技术有限公司 修饰性核苷酸及其用途
EP2149375A1 (en) * 2008-07-28 2010-02-03 Despharma Kft. Compositions for the treatment of dermatological diseases, and uses thereof
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
FR3041540B1 (fr) * 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante a rincer, contenant de l'ivermectine.

Also Published As

Publication number Publication date
AU2024202211A1 (en) 2024-05-02
JP7470449B2 (ja) 2024-04-18
AU2018282905A1 (en) 2019-12-19
EP4241769A2 (en) 2023-09-13
EP4241769A3 (en) 2023-11-08
US20210361689A1 (en) 2021-11-25
US20200360415A1 (en) 2020-11-19
ES2981923T3 (es) 2024-10-11
PT3638251T (pt) 2024-05-22
DK3638251T3 (da) 2024-05-13
CN110753549A (zh) 2020-02-04
BR112019026073A2 (pt) 2020-06-30
BR112019026073B1 (pt) 2021-11-03
EP3638251A1 (en) 2020-04-22
US20230125677A1 (en) 2023-04-27
CA3066722A1 (en) 2018-12-20
EP3638251A4 (en) 2021-03-10
KR20200014904A (ko) 2020-02-11
US20180353529A1 (en) 2018-12-13
US11096954B2 (en) 2021-08-24
JP7148994B2 (ja) 2022-10-06
JP2022183154A (ja) 2022-12-08
KR20230031370A (ko) 2023-03-07
WO2018231863A1 (en) 2018-12-20
FI3638251T3 (fi) 2024-04-29
BR122021011439B1 (pt) 2022-03-29
AU2018282905B2 (en) 2022-06-02
JP2020523322A (ja) 2020-08-06
AU2022224829A1 (en) 2022-09-29
EP3638251B1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
EP3452597A4 (en) METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS
CA2956871C (en) Compounds active towards bromodomains
PH12017501611A1 (en) Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
MX2019012978A (es) Composiciones para el cuidado bucal y metodos para utilizar las composiciones.
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
EP3710036A4 (en) STABLE ASCORBIC ACID COMPOSITIONS AND METHOD FOR THEIR USE
EP3474869A4 (en) COMPOSITIONS DERIVED FROM HUMAN TISSUE AND USES THEREOF
MX2021016050A (es) Formulaciones transdermicas.
EP3570826A4 (en) N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
MX2018013184A (es) Composiciones de saponinas y extractos vegetales.
PH12020550217A1 (en) Nutrient-spore formulations and uses thereof
EP3687501A4 (en) INIPARIB FORMS AND USES THEREOF
EP3687491A4 (en) HAIR CARE COMPOSITIONS AND METHODS
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
EP3644971A4 (en) CLOSTRIDIAL NEUROTOXIN FORMULATIONS AND USE
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
EP3701942A4 (en) SOLUBILIZATION OF CHLORHEXIDINE BASE, ANTISEPTIC AND DISINFECTANT COMPOSITIONS
WO2016130581A3 (en) Combination cancer therapy
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
PH12018501758A1 (en) Oritavancin formulations
MX2019010640A (es) Formas cristalinas de acido obeticolico.
MX2021014806A (es) Composiciones para el cuidado bucal y sus usos.
EP3664800A4 (en) THERAPEUTIC FORMULATIONS AND USES THEREOF